Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non–Small-Cell Lung Cancer

Are comedications at pembrolizumab start associated with worse overall survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC)?In this cohort study of 41 529 patients with NSCLC, after adjustment for several confounders, exposure to antibiotics (with the exception of macrolide and penicillin), to high doses of steroids (>20 mg per day of equivalent prednisone), and to proton pump inhibitors at the beginning of pembrolizumab treatment were associated with worse OS.These findings suggest that comedications should be monitored carefully in patients with immunotherapy.

Corresponding Author: Stéphanie Foulon, MD, PhD, Biostatistics and Epidemiology Office, Gustave Roussy, Paris-Saclay University, 114 Rue Edouard Vaillant, 94800 Villejuif, France (stephanie.foulon@gustaveroussy.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.